Marumo K, Murai M, Deguchi N, Ikeuchi K, Tazaki H
Department of Urology, School of Medicine, Keio University, Tokyo, Japan.
Keio J Med. 1990 Jun;39(2):97-101. doi: 10.2302/kjm.39.97.
Immunologic and antitumor effects of human recombinant interferon-gamma were studied in patients with renal cell carcinoma. A daily dose of 6 to 12 x 10(6) units/m2 of interferon-gamma was given by intravenous drip infusion or intramuscular injection to nine patients over a period varying from two to 16 weeks. Antibody-dependent cell-mediated cytotoxicity and OKIa1-positive monocytes count increased significantly after the therapy was started. Interferon-gamma transiently increased OKT3- and OKT4- positive lymphocyte count. Tumor regression was not observed when clinical response was evaluated in seven patients. Two others, who had no measurable metastases, were not evaluated, because interferon-gamma were given to them as post-operative adjuvant therapy. Our results indicate that interferon-gamma stimulated monocytes and enhanced cell-mediated cytotoxicity; they also suggest the necessity of combining monoclonal antibodies and other biological response modifiers that effect tumor-associated antigens.
在肾细胞癌患者中研究了人重组干扰素-γ的免疫和抗肿瘤作用。对9例患者静脉滴注或肌肉注射干扰素-γ，剂量为每日6至12×10⁶单位/m²，疗程为2至16周不等。治疗开始后，抗体依赖性细胞介导的细胞毒性和OKIa1阳性单核细胞计数显著增加。干扰素-γ使OKT3和OKT4阳性淋巴细胞计数短暂增加。在评估7例患者的临床反应时未观察到肿瘤消退。另外2例无可测量转移灶的患者未进行评估，因为给他们使用干扰素-γ作为术后辅助治疗。我们的结果表明，干扰素-γ刺激单核细胞并增强细胞介导的细胞毒性；它们还提示联合使用单克隆抗体和其他作用于肿瘤相关抗原的生物反应调节剂的必要性。
